Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Compounded Pyrimethamine: 'Personalized Medicine' Or 'Unapproved Drug'?

Executive Summary

Responding to the Express Scripts' deal to promote use of a compounded alternative to its drug, Turing says physicians shouldn't prescribe the compound, since it is an unapproved and unsafe drug. But the compounder, Imprimis, says each prescription is custom-made, making it a "personalized medicine."


Related Content

Compounding For Lower Prices Not PBMs’ New ‘Game Plan,’ Lawmakers Told
Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"


Related Companies